Post-transcriptional Regulation by MicroRNA-21 and let-7a MicroRNA in Paediatric Cholesteatoma

被引:28
作者
Chen, X. [1 ]
Qin, Z. [1 ]
机构
[1] Zhengzhou Univ, Inst Clin Med, Dept Otolaryngol, Affiliated Hosp 1, Zhengzhou 450052, Henan, Peoples R China
关键词
CHOLESTEATOMA; CHILD; ADULT; MICRORNA; 21; LET-7; PHOSPHATASE AND TENSIN HOMOLOGUE (PTEN); PROGRAMMED CELL DEATH PROTEIN 4 (PDCD4); HIGH-MOBILITY GROUP AT-HOOK 2 (HMGA2); MOBILITY GROUP A2; BONE DESTRUCTION; EXPRESSION; GENE; PROLIFERATION; CANCER; HMGA2; PTEN; OVEREXPRESSION; BIOGENESIS;
D O I
10.1177/147323001103900607
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
This study investigated the role of microRNA-21 (miR-21) and let-7a microRNA in paediatric and adult cholesteatoma. Total RNA and protein were isolated from the cholesteatoma specimens and normal skin of 10 adults and 10 children. Levels of miR-21 and let-7a microRNA were assessed by real-time reverse transcription-polymerase chain reaction, and levels of phosphatase and tensin homologue (PTEN), programmed cell death 4 (PDCD4) and high mobility group AT-hook 2 (HMGA2) protein were assessed by Western blot analysis. Levels of miR-21 and let-7a microRNA were significantly higher in cholesteatoma tissue compared with normal skin, especially in paediatric patients. PUN, PDCD4 and HMGA2 protein levels were significantly lower in paediatric versus adult cholesteatoma patients. It is possible that upregulation of miR-21 leads to higher tumour cell proliferation and invasion of cholesteatoma in children than adults, and the benign nature of cholesteatoma may be due to a balance between let-7a microRNA and miR-21. These data may help to identify targets for miRNA- and protein-based therapeutic interventions for the non-surgical or adjunctive treatment of cholesteatoma.
引用
收藏
页码:2110 / 2118
页数:9
相关论文
共 40 条
  • [1] MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004)
    Bartel, David P.
    [J]. CELL, 2007, 131 (04) : 11 - 29
  • [2] Immunobiological peculiarities of cholesteatoma in children: Quantification of epithelial proliferation by MIB 1
    Bujia, J
    Holly, A
    AntoliCandela, F
    Tapia, MG
    Kastenbauer, E
    [J]. LARYNGOSCOPE, 1996, 106 (07) : 865 - 868
  • [3] A Parsimonious Model for Gene Regulation by miRNAs
    Djuranovic, Sergej
    Nahvi, Ali
    Green, Rachel
    [J]. SCIENCE, 2011, 331 (6017) : 550 - 553
  • [4] The tumor suppressor PTEN is necessary for human sprouty 2-mediated inhibition of cell proliferation
    Edwin, F
    Singh, R
    Endersby, R
    Baker, SJ
    Patel, TB
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (08) : 4816 - 4822
  • [5] Fabjani G, 2005, ONCOL REP, V14, P737
  • [6] Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas
    Fedele, M
    Battista, S
    Kenyon, L
    Baldassarre, G
    Fidanza, V
    Klein-Szanto, AJP
    Parlow, AF
    Visone, R
    Pierantoni, GM
    Outwater, E
    Santoro, M
    Croce, CM
    Fusco, A
    [J]. ONCOGENE, 2002, 21 (20) : 3190 - 3198
  • [7] Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells
    Frankel, Lisa B.
    Christoffersen, Nanna R.
    Jacobsen, Anders
    Lindow, Morten
    Krogh, Anders
    Lund, Anders H.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (02) : 1026 - 1033
  • [8] Cholesteatoma Growth and Proliferation: Posttranscriptional Regulation by MicroRNA-21
    Friedland, David R.
    Eernisse, Rebecca
    Erbe, Christy
    Gupta, Nidhi
    Cioffi, Joseph A.
    [J]. OTOLOGY & NEUROTOLOGY, 2009, 30 (07) : 998 - 1005
  • [9] Characterization of patterns of expression of protein kinase C-α, -δ -η, -γ and -ζ and their correlations to p53, galectin-3, the retinoic acid receptor-β and the macrophage migration inhibitory factor (MIF) in human cholesteatomas
    Ghanooni, Rose
    Decaestecker, Christine
    Simon, Patricia
    Gablus, Hans-Joachim
    Hassid, Sergio
    Choufani, Georges
    [J]. HEARING RESEARCH, 2006, 214 (1-2) : 7 - 16
  • [10] Gordanpour A, 2011, ANTICANCER RES, V31, P403